Denali Therapeutics Inc (NASDAQ: DNLI) flaunted slowness of -0.87% at $29.63, before settling in for the price of $29.89 at the close. Taking a more long-term approach, DNLI posted a 52-week range of $14.56-$33.33.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
In the past 5-years timespan, the Healthcare sector firm’s annual sales growth was 264.19%. Meanwhile, its Annual Earning per share during the time was -21.99%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -162.14%. This publicly-traded company’s shares outstanding now amounts to $138.39 million, simultaneously with a float of $125.37 million. The organization now has a market capitalization sitting at $4.26 billion. At the time of writing, stock’s 50-day Moving Average stood at $28.14, while the 200-day Moving Average is $22.32.
Denali Therapeutics Inc (DNLI) Ownership Facts and Figures
Sometimes it is also beneficial to study the sentiment of large-scale investors towards the stock of the Denali Therapeutics Inc industry. Denali Therapeutics Inc’s current insider ownership accounts for 12.89%, in contrast to 84.41% institutional ownership. According to the most recent insider trade that took place on Nov 11 ’24, this organization’s Director sold 59,441 shares at the rate of 32.51, making the entire transaction reach 1,932,665 in total value, affecting insider ownership by 9,220. Preceding that transaction, on Nov 07 ’24, Company’s COFO and Secretary sold 15,558 for 29.91, making the whole transaction’s value amount to 465,286. This particular insider is now the holder of 178,066 in total.
Denali Therapeutics Inc (DNLI) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.76 per share during the current fiscal year.
Denali Therapeutics Inc’s EPS decrease for this current 12-month fiscal period is -162.14% and is forecasted to reach -2.85 in the upcoming year.
Denali Therapeutics Inc (NASDAQ: DNLI) Trading Performance Indicators
Let’s observe the current performance indicators for Denali Therapeutics Inc (DNLI). It’s Quick Ratio in the last reported quarter now stands at 9.98. The Stock has managed to achieve an average true range (ATR) of 1.45.
In the same vein, DNLI’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -2.76, a figure that is expected to reach -0.82 in the next quarter, and analysts are predicting that it will be -2.85 at the market close of one year from today.
Technical Analysis of Denali Therapeutics Inc (DNLI)
Now, what If we examine the latest scores posted by [Denali Therapeutics Inc, DNLI]. During the last 5-days, its volume was lower the volume of 1.07 million it reported in year-ago period. During the previous 9 days, stock’s Stochastic %D was recorded 60.54% While, its Average True Range was 1.59.
Raw Stochastic average of Denali Therapeutics Inc (DNLI) in the period of the previous 100 days is set at 72.77%, which indicates a major rise in contrast to 52.44% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 55.87% that was higher than 50.92% volatility it exhibited in the past 100-days period.
